Granite Investment Partners LLC Decreases Stake in Establishment Labs Holdings Inc. $ESTA

Granite Investment Partners LLC lessened its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 30.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 161,017 shares of the company’s stock after selling 71,683 shares during the period. Granite Investment Partners LLC owned approximately 0.56% of Establishment Labs worth $6,600,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ESTA. Simplify Asset Management Inc. acquired a new position in shares of Establishment Labs during the 3rd quarter worth $1,555,000. Tejara Capital Ltd boosted its holdings in Establishment Labs by 31.2% during the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock worth $4,201,000 after buying an additional 24,386 shares in the last quarter. Woodson Capital Management LP grew its position in Establishment Labs by 113.3% during the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after buying an additional 255,000 shares during the period. Affinity Asset Advisors LLC increased its holdings in Establishment Labs by 19.6% in the second quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock valued at $14,302,000 after buying an additional 54,863 shares in the last quarter. Finally, Hood River Capital Management LLC lifted its position in shares of Establishment Labs by 138.2% during the 2nd quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock valued at $2,269,000 after acquiring an additional 30,825 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Trading Up 0.2%

Shares of ESTA stock opened at $76.00 on Monday. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -26.76 and a beta of 0.99. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. The firm has a 50-day moving average price of $70.82 and a 200 day moving average price of $57.14. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $78.24.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Citigroup upped their target price on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Mizuho lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 price objective on shares of Establishment Labs in a research report on Monday, January 12th. Finally, BTIG Research raised their target price on shares of Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.86.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.